Betty Escalante
Family · Corpus Christi, TXNPI 1265918387
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 24.5% of the total.
Across 34 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$149
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
- Eisai Inc.$90
- Vanda Pharmaceuticals Inc.$77
- Sunovion Pharmaceuticals Inc.$48
- Takeda Pharmaceuticals U.S.A., Inc.$35
- plus $119 from 7 others
What the payments were for
- Food & beverage$56292%
- Education$478%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $149 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $91 |
| Eisai Inc. | 5 | $90 |
| Vanda Pharmaceuticals Inc. | 5 | $77 |
| Sunovion Pharmaceuticals Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| AbbVie | 2 | $26 |
| Alkermes, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Bausch Health US, LLC | 1 | $17 |
| Merck | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Indivior Inc. | 1 | $11 |
How this compares
$609 in reported general payments places this provider in the 55th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Linezolid | 11 | $899 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $97 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $78 |
Paid to pharmacies, not to this prescriber.
Other family in Corpus Christi
- Stephanie RodriguezCorpus Christi$159K
- Katie MontgomeryCorpus Christi$29K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.